Fressenius introduces Moxifloxacin injection in Freeflex bags

Fresenius Kabi USA announced Friday it has introduced the anti-infective Moxifloxacin injection 400 mg per 250 mL in Freeflex bags.

This is a first-to-market alternative for this injectable drug, which was previously available only from the innovator.
  
"Fresenius Kabi is pleased to offer this first and only alternative to Avelox Injection for our customers and the patients they serve,” Fresenius Kabi USA President and CEO John Ducker said. “The introduction of Moxifloxacin expands both our leading anti-infective portfolio and our ready-to-use intravenous offerings in the U.S."

Moxifloxacin is the third premix product Fresenius Kabi has introduced in the United States using the company’s proprietary Freeflex delivery system since 2013. Freeflex is a non-PVC and non-DEHP flexible bag for infusion solutions using patented port technology and clear labeling.
 
Moxifloxacin injection is indicated for the treatment of adults with infections caused by susceptible isolates of the designated microorganisms in acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia, skin and skin structure infections and complicated intra-abdominal infections. 

Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s U.S. headquarters is in Lake Zurich, Illinois, and its global headquarters are in Bad Homburg, Germany.